Patient Web Site | Site Map | Contact Us

Health care professional tools

Explore this collection of health care professional resources that contains useful information and valuable communication tools to support your practice and educational and professional presentations.

• Formulary Tool
  The Formulary Database is a simple-to-use tool that allows you to determine availability of CRESTOR under specific benefit plans, by location. Simply select your state and up to six health plans. Your results will show available coverage, along with any restrictions that may apply.
• Mobile Lipid Clinic™
  The Mobile Lipid Clinic is a software innovation that allows physicians to assess patients with lipid disorders on the spot. The free programs run on both the Palm™ and Windows^® operating systems.
• Web resources
  A sampling of the best the Web has to offer in terms of patient education materials, clinical practice recommendations, current news, professional education opportunities, conferences, and more.
• Journal reprints
  Review findings from major studies on the safety and efficacy of CRESTOR, including the STELLAR trial.
• OnDemand podcasts
  A collection of OnDemand slide presentations covering topics such as treating patients to goal and FDA rulings on the use of statins. Check back frequently for new and updated presentations.

CRESTOR is indicated

¹
As an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and TG levels and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia.

As an adjunct to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels.

The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined; long-term outcomes studies are currently under way.

CRESTOR is contraindicated

¹
In patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers.

Important safety information about CRESTOR

¹
Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level, but are increased at the highest dose (40 mg).

CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age ≥ 65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir.

Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.

CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose.

It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (eg, semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume substantial quantities of alcohol.

In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%).¹³

Mobile Lipid Clinic™ is a trademark of Mobile Lipid Clinic.
Windows^® is a registered trademark of Microsoft Corporation.
Palm™is a trademark of Palm Trademark Holding Company, LLC.

Please see full Prescribing Information for CRESTOR.

CRESTOR was licensed from SHIONOGI & CO. LTD, Osaka, Japan.